These comparisons showed that the NSCLC patients had higher rates of older age at diagnosis, smoking, dyslipidemia, hypertension, and family cancer history than the CRC patients when KRAS mutations were present (Table 3). This evidence concerns the gene KRAS and non-small cell lung carcinoma.